Maze Therapeutics (MAZE) Operating Expenses (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Operating Expenses data on file, last reported at $46.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 31.5% year-over-year to $46.6 million; the trailing twelve-month figure through Mar 2026 stood at $154.1 million (up 31.33% YoY), and the FY2025 full-year result was $142.9 million, up 30.01% from the prior year.
• Operating Expenses climbed to $46.6 million in Q1 2026, from $38.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $46.6 million in Q1 2026 to a low of $25.4 million in Q2 2024.
• A 3-year average of $33.3 million and a median of $33.0 million in 2025 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 43.34% in 2025, while the deepest fall reached 23.33% in 2025.
• Tracing MAZE's Operating Expenses over 3 years: stood at $29.7 million in 2024, then climbed by 28.03% to $38.1 million in 2025, then advanced by 22.32% to $46.6 million in 2026.
• Business Quant data shows MAZE's Operating Expenses at $46.6 million in Q1 2026, $38.1 million in Q4 2025, and $33.0 million in Q3 2025.